Law360, New York (August 21, 2012, 1:36 PM ET) -- Pfizer Inc. on Friday urged the First Circuit to uphold the dismissal of Blue Cross Blue Shield of Louisiana, several health plans and other third-party payors from multidistrict litigation over alleged off-label marketing of epilepsy drug Neurontin, saying the payors couldn’t prove any direct injury from Pfizer’s actions.
According to a brief filed by the drugmaker on behalf of itself and subsidiary Warner-Lambert Co. LLC, U.S. District Judge Patti B. Saris had correctly dismissed the case from the MDL in December 2010. Judge Saris ruled that...
Pfizer Tells 1st Circ. Neurontin MDL Shows No Proof Of Harm
To view the full article, take a free trial now.
